Skip to main content
SpringerLink
Log in

Systemic Therapy: Selection of Patients

Endocrine Therapy

  • Chapter
  • First Online:
Breast Cancer, a Heterogeneous Disease Entity

Abstract

About two-thirds of all breast tumours are hormone receptor-positive, and therefore expectedly hormone-sensitive. The proportion of ER-positive breast cancers is even higher among early breast cancers. The rationale the currently applied endocrine manipulations is oestrogen deprivation, either by competitive blockade of the hormone at the level of its receptor or by inhibition of its synthesis. The automatic administration of endocrine agents to all patients with hormone receptor-positive breast cancer would mean overtreatment, and would cause unnecessary morbidity to many patients. The adverse effects of endocrine therapies include gynaecologic toxicity and sexual dysfunction, osteoporosis, arthralgia, effects on the nervous system and cognitive dysfunction, thus deteriorating health-related quality of life (HRQOL). An effort should be made to balance the issues relating to the risk of relapse and the extent of hormone sensitivity, and hence the expected benefit of therapy, together with the risks accompanying the endocrine therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albain K, Barlow W, Shak S et al (2007) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Breast Cancer Res Treat 106(Suppl 1):late breaking abstract, #10

    Google Scholar 

  • Anttinen J, Kautiainen H, Kuopio T (2006) Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients. Br J Cancer 94:147–151

    Article  PubMed  CAS  Google Scholar 

  • Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261

    Article  PubMed  CAS  Google Scholar 

  • Bardou VJ, Arpino G, Elledge RM et al (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973–1979

    Article  PubMed  CAS  Google Scholar 

  • Berglund G, Nystedt M, Bolund C et al (2001) Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 19:2788–2796

    PubMed  CAS  Google Scholar 

  • Bertelli G, Hall E, Ireland E et al (2010) Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomized controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Ann Oncol 21:498–505

    Article  PubMed  CAS  Google Scholar 

  • Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):10–14

    Article  Google Scholar 

  • Borg A, Baldetorp B, Ferno M et al (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137–144

    Article  PubMed  CAS  Google Scholar 

  • Borges S, Seta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74

    CAS  Google Scholar 

  • Brauch H, Jordan C (2009) Targeting tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the ‘personalised’ approach. Eur J Cancer 45:2274–2283

    Article  PubMed  CAS  Google Scholar 

  • Briot K, Tubiana-Hulin M, Bastit L et al (2010) Effect of switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127–134

    Article  PubMed  CAS  Google Scholar 

  • Bucchi L, Barchielli A, Ravaioli A et al (2005) Screen-detected vs. clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. Br J Cancer 92:156–161

    Article  PubMed  CAS  Google Scholar 

  • Buijs C, Willemse PH, de Vries EG et al (2009) Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients. Int J Gynecol Cancer 19:677–681

    Article  PubMed  Google Scholar 

  • Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16:223–234

    Article  PubMed  Google Scholar 

  • Cardoso F, Van’t Veer L, Rutgers E et al (2008) Clinical application of the 70–gene profile: the MINDACT trial. J Clin Oncol 26:729–735

    Article  PubMed  Google Scholar 

  • Cella D, Fallowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284

    Article  PubMed  Google Scholar 

  • Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492

    Article  PubMed  CAS  Google Scholar 

  • Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119–127

    Article  PubMed  CAS  Google Scholar 

  • Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570

    Article  PubMed  CAS  Google Scholar 

  • Cortesi L, Chiuri VE, Ruscelli S et al (2006) Prognosis of screen-detected breast cancers: results of a population based study. BMC Cancer 6:17

    Article  PubMed  Google Scholar 

  • Creighton CJ, Osborne K, van de Vijver MJ et al (2009) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114:287–299

    Article  PubMed  CAS  Google Scholar 

  • Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. Clin Oncol 25(25):3877–3883

    Article  Google Scholar 

  • Crivellari D, Sun Z, Coates AS et al (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26:1972–1979

    Article  PubMed  CAS  Google Scholar 

  • Curigliano G, Viale G, Bagnardi V et al (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 34:5693–5699

    Article  Google Scholar 

  • Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143–1149

    Article  PubMed  CAS  Google Scholar 

  • Day R (2001) National Surgical Adjuvant Breast and Bowel Project P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 949:143–150

    Article  PubMed  CAS  Google Scholar 

  • De Haes H, Olschewski M, Kaufmann M et al (2003) Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol 21:4510–4516

    Article  PubMed  Google Scholar 

  • De Placido S, De Laurentiis M, Carlomagno C et al (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039–1046

    PubMed  Google Scholar 

  • De Sombre ER, Puca GA, Jensen EV (1969) Purification of an estrophilic protein from calf uterus. Proc Natl Acad Sci U S A 64:148–154

    Article  PubMed  Google Scholar 

  • Dizdar O, Ozçakar L, Malas FU et al (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27:4955–4960

    Article  PubMed  Google Scholar 

  • Dong W, Berry DA, Bevers TB et al (2008) Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17:1096–1103

    Article  CAS  Google Scholar 

  • Dowsett M, Cuzick J, Wale C et al (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23:7512–7517

    Article  PubMed  CAS  Google Scholar 

  • Dowsett M, Houghton J, Iden C et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818–826

    Article  PubMed  CAS  Google Scholar 

  • Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial. J Clin Oncol 26:1059–1065

    Article  PubMed  CAS  Google Scholar 

  • Dowsett M, Cuzick J, Ingle J et al (2010a) Meta-analysis of breast cancer outcomes in adjuvant trials with aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518

    Article  CAS  Google Scholar 

  • Dowsett M, Cuzick J, Wale C et al (2010b) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a transATAC study. J Clin Oncol 28:1829

    Article  Google Scholar 

  • Duffy SR, Distler W, Howell A et al (2009) A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstetr Gynecol 200:80.e1–80.e7

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Google Scholar 

  • Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Bone Miner Res 21:1215–1223

    Article  PubMed  CAS  Google Scholar 

  • Ellis MJ, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 105(Suppl 1):33–43

    Article  PubMed  CAS  Google Scholar 

  • Fallowfield LJ, Bliss JM, Porter LS et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910–917

    Article  PubMed  CAS  Google Scholar 

  • Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52(9):2594–2598

    Article  PubMed  CAS  Google Scholar 

  • Fogelman I, Blake GM, Blamey R et al (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14:1001–1006

    Article  PubMed  CAS  Google Scholar 

  • Fontaine C, Meulemans A, Huizing M et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376–381

    Article  PubMed  CAS  Google Scholar 

  • Geisler J, Lonning PE, Krag LE et al (2006) Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 42:2968–2975

    Article  PubMed  CAS  Google Scholar 

  • Gill PG, Farshid G, Luke CG et al (2004) Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13:15–22

    Article  PubMed  CAS  Google Scholar 

  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment–induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820–828

    Article  PubMed  CAS  Google Scholar 

  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840–849

    Article  PubMed  CAS  Google Scholar 

  • Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691

    Article  PubMed  CAS  Google Scholar 

  • Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318

    Article  PubMed  CAS  Google Scholar 

  • Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121

    Article  PubMed  CAS  Google Scholar 

  • Gonzales-Angulo AM, Litton JK, Broglio KR et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700–5706

    Article  Google Scholar 

  • Goss PE (2007) Letrozole in the extended adjuvant setting: MA-17. Breast Cancer Res Treat 105:45–53

    Article  PubMed  CAS  Google Scholar 

  • Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  PubMed  CAS  Google Scholar 

  • Groenvold M, Fayers PM, Petersen MA, Mouridsen HT (2006) Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:275–284

    Article  PubMed  CAS  Google Scholar 

  • Hadji P, Ziller M, Kieback DG et al (2009) Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomized substudy. Ann Oncol 20:1203–1209

    Article  PubMed  CAS  Google Scholar 

  • Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481

    PubMed  CAS  Google Scholar 

  • Immonen-Raiha P, Kauhava L, Parvinen I et al (2005) Mammographic screening reduces risk of breast carcinoma recurrence. Cancer 103:474–482

    Article  PubMed  Google Scholar 

  • Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  PubMed  CAS  Google Scholar 

  • Jakesz R, Greil R, Gnant M et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845–1853

    Article  PubMed  CAS  Google Scholar 

  • Jenkins V, Shilling V, Fallowfield L et al (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61–66

    Article  PubMed  Google Scholar 

  • Jenkins VA, Ambroisine LM, Atkins L et al (2008) Effects of anastrozole on cognitive performance in postmenopausal women: a randomized, double-blind chemoprevention trial (IBIS II). Lancet Oncol 9:953–961

    Article  PubMed  CAS  Google Scholar 

  • Jim HSC, Donovan KA, Small BJ et al (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:1776–1783

    Article  PubMed  Google Scholar 

  • Joensuu H, Lehtimaki T, Holli K et al (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064–1073

    Article  PubMed  CAS  Google Scholar 

  • Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287–1293

    Article  PubMed  CAS  Google Scholar 

  • Klemi PJ, Joensuu H, Toikkanen S et al (1992) Aggressiveness of breast cancers found with and without screening. BMJ 304:467–469

    Article  PubMed  CAS  Google Scholar 

  • Klemi PJ, Parvinen I, Pylkkanen L et al (2002) Significant improvement in breast cancer survival through population-based mammography screening, Breast 12:308–313

    Article  Google Scholar 

  • Knoop AS, Bentzen SM, Nielsen MM et al (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376–3384

    PubMed  CAS  Google Scholar 

  • Kristensen B, Ejlertsen B, Dalgaard P et al (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992–997

    PubMed  CAS  Google Scholar 

  • LHRH agonists in Early Breast Cancer Overview group (2007) Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723

    Google Scholar 

  • Liu S, Chia SK, Mehl E et al (2009) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 118:45–56

    Article  Google Scholar 

  • Love RR, Cameron L, Connell BL, Leventhal H (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151:1842–1847

    Article  PubMed  CAS  Google Scholar 

  • Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856

    Article  PubMed  CAS  Google Scholar 

  • Love RR, Duc NB, Havighurst TC et al (2003) Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453–457

    Article  PubMed  CAS  Google Scholar 

  • Machado F, Rodriguez R, Leon JP et al (2005) Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 26:257–265

    PubMed  CAS  Google Scholar 

  • Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965–1971

    Article  PubMed  CAS  Google Scholar 

  • Mauriac L, Keshaviah A, Debled M et al (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859–867

    Article  PubMed  CAS  Google Scholar 

  • McGuire WL (1973) Estrogen receptors in human breast cancer. J Clin Invest 52:73–77

    Article  PubMed  CAS  Google Scholar 

  • Mohsin SK, Weiss H, Havighurst T et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17:1545–1554

    Article  PubMed  CAS  Google Scholar 

  • Molino A, Pavarana M, Micciolo R et al (2000) Comparative study of clinical, pathological and biological characteristics of symptomatic versus asymptomatic breast cancers. Ann Oncol 11:581–586

    Google Scholar 

  • Morales L, Pans S, Verschueren K et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. Clin Oncol 26:3147–3152

    Article  Google Scholar 

  • Mortimer JE, Boucher L, Baty J et al (1999) Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17:1488–1492

    PubMed  CAS  Google Scholar 

  • Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Tu D, Ingle JN et al (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup Trial MA.17. J Clin Oncol 26:1956–1964

    CAS  Google Scholar 

  • Nickelsen T, Lufkin EG, Riggs BL et al (1999) Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24:115–128

    Article  PubMed  CAS  Google Scholar 

  • Nystedt M, Berglund G, Bolund C (2000) Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer. Acta Oncol 39:959–968

    Article  PubMed  CAS  Google Scholar 

  • Nystedt M, Berglund G, Bolund C et al (2003) Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 21:1836–1844

    Article  PubMed  CAS  Google Scholar 

  • Osborne CK, McGuire WL (1978) Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am 58:777–788

    PubMed  CAS  Google Scholar 

  • Paganini-Hill AP, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165–176

    Article  PubMed  CAS  Google Scholar 

  • Pálka I, Kelemen G, Ormándi K et al (2008) Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 14:161–167

    Article  PubMed  Google Scholar 

  • Perez EA, Jesse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCICCTG MA.17. J Clin Oncol 24:3629–3635

    Article  PubMed  CAS  Google Scholar 

  • Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78–84

    PubMed  CAS  Google Scholar 

  • Rydén L, Jirstrom K, Bendahl PO et al (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23:4695–4704

    Article  PubMed  Google Scholar 

  • Rydén L, Göran C, Landberg Ć et al (2008) HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 109:351–357

    Google Scholar 

  • Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436

    Article  PubMed  CAS  Google Scholar 

  • Sestak I, Cuzick J, Sapunar F et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective exploratory analysis. Lancet Oncol 9:866–872

    Article  PubMed  Google Scholar 

  • Sestak I, Sapunar F, Cuzick J (2009) Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27:4961–4965

    Article  PubMed  CAS  Google Scholar 

  • Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116

    Article  PubMed  CAS  Google Scholar 

  • Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721–728

    Article  PubMed  Google Scholar 

  • Stål O, Borg A, Ferno M et al (2000) ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11:1545–1550

    Article  PubMed  Google Scholar 

  • The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Google Scholar 

  • Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  PubMed  Google Scholar 

  • Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463

    Article  PubMed  Google Scholar 

  • Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846–3852

    Article  PubMed  Google Scholar 

  • Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931–6940

    Article  PubMed  CAS  Google Scholar 

  • Yaffe K, Krueger K, Sarkar S et al (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207–1213

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncotherapy, University of Szeged, Korányi fasor 12, 6720, Szeged, Hungary

    Zsuzsanna Kahán

Authors
  1. Zsuzsanna Kahán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zsuzsanna Kahán .

Editor information

Editors and Affiliations

  1. , University of Szeged, Department of Oncotherapy, Korányi fasor 12, Szeged, 6720, Hungary

    Zsuzsanna Kahán

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Kahán, Z. (2011). Systemic Therapy: Selection of Patients. In: Kahán, Z. (eds) Breast Cancer, a Heterogeneous Disease Entity. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0489-3_12

Download citation

Publish with us

Policies and ethics

Search

Navigation